R Manjunatha Kini

This inventor holds 15 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignees: Virginia Commonwealth University, National University of Singapore, Institute of Zoology, Slovak Academy of Sciences. Active years: 1999-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: R Manjunatha Kini. Retrieved from https://idiyas.com/inventor/r-manjunatha-kini

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 1)

% Patents Active = 86.7

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 2.4

ph-index = 4

Forward Citations = 42(Granted Patents)

Location History:

Singapore, IN (2000)
Singapore, SG (1999 - 2022)

Company Filing History:

9 out of 420

Virginia Commonwealth University

patents

4 out of 857

National University of Singapore

patents

1 out of 1

Institute of Zoology, Slovak Academy of Sciences

patent

4. 1 out of 330

Isis Innovation Limited

patents

5. 1 out of 140

Singapore Health Services Pte Ltd

patents

where one patent can have more than one assignee

Years Active: 1999-2022

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11266710 - Angio-3 for treatment of retinal angiogenic diseases (2022-03-08),

2. 10906946 - Thrombin inhibitors (2021-02-02),

3. 9217027 - Thrombin inhibitor (2015-12-22),

4. 7317003 - Small peptides having anti-angiogenic and endothelial cell inhibition activity (2008-01-08),

5. 6613745 - Therapeutic molecules derived from snake venom (2003-09-02),

6. 6258550 - Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site (2001-07-10),

7. 6200954 - Small peptides having potent anti-angiogenic activity (2001-03-13),

8. 6147189 - Polypeptides that include conformation-constraining groups which flank a (2000-11-14),

9. 6111069 - Polypeptides that include conformation-constraining groups which flank a (2000-08-29),

10. 6100044 - Polypeptides that include conformation-constraining groups which flank a (2000-08-08),

11. 6084066 - Polypetides that include conformation-constraining groups which flank a (2000-07-04),

12. 5965698 - Polypeptides that include conformation-constraining groups which flank a (1999-10-12),

13. 5952465 - Polypeptides that include conformation-constraining groups which flank a (1999-09-14),

14. 5948887 - Polypeptides that include conformation-constraining groups which flank a (1999-09-07),

15. 5928896 - Polypeptides that include conformation-constraining groups which flank a (1999-07-27),

Title: R Manjunatha Kini: Innovator in Retinal Treatment and Thrombin Inhibition

Introduction

R Manjunatha Kini is a prominent inventor based in Singapore, known for his significant contributions to the fields of medical science and biotechnology. With a total of 15 patents to his name, he has made remarkable advancements in the treatment of retinal diseases and thrombin inhibition.

Latest Patents

Among his latest patents is Angio-3, which focuses on the treatment of retinal angiogenic diseases. This innovative disclosure outlines methods for treating retinal angiogenic conditions in subjects by administering an effective amount of an Angio-3 peptide. Another notable invention is related to thrombin inhibitors, where he provides isolated peptides, variants, and fragments that can bind with high specificity to thrombin, effectively inhibiting its activity. This invention also includes potential applications in diagnosis, treatment, coating of medical devices, and nucleic acids encoding the same.

Career Highlights

R Manjunatha Kini has had a distinguished career, working with esteemed institutions such as Virginia Commonwealth University and the National University of Singapore. His work has significantly impacted the medical field, particularly in developing therapeutic solutions for complex health issues.

Collaborations

He has collaborated with notable professionals in his field, including Herbert J Evans and Cho Yeow Koh, further enhancing the scope and impact of his research.

Conclusion

R Manjunatha Kini's innovative work in retinal treatment and thrombin inhibition showcases his dedication to advancing medical science. His contributions continue to pave the way for new therapeutic approaches and improved patient outcomes.

Profile summary based on public USPTO records.